NewcelX (NCEL) Accounts Payables (2019 - 2025)
NewcelX (NCEL) posted quarterly Accounts Payables of $251000.0 for Q4 2025, down 58.51% year-over-year from $605000.0 in Q4 2024, and down 61.97% quarter-over-quarter from $660000.0 in Q2 2025.
NewcelX (NCEL) Accounts Payables (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Accounts Payables for 7 consecutive years, with $251000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables fell 58.51% year-over-year to $251000.0; the TTM figure through Dec 2025 stood at $251000.0 (down 58.51% YoY), while the FY2025 annual figure was $251000.0, down 58.51% from the prior year.
- Accounts Payables fell to $251000.0 in Q4 2025 per NCEL's latest filing, from $660000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $4.0 million in Q2 2021 and bottomed at $164000.0 in Q2 2024.
- Historically, Accounts Payables has averaged $1.1 million across 5 years, with a median of $483500.0 in 2022.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 88.98% — and 2025, when it surged 302.44%.
- NewcelX's Accounts Payables stood at $1.7 million in 2021, then slumped by 79.16% to $362000.0 in 2022, then slumped by 37.57% to $226000.0 in 2023, then jumped by 167.7% to $605000.0 in 2024, then sank by 58.51% to $251000.0 in 2025.
- Business Quant data shows NCEL's Accounts Payables at $251000.0 in Q4 2025, $660000.0 in Q2 2025, and $605000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 35.57 Mn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 251,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 251,000.00 |
| Jun 30, 2025 | 660,000.00 |
| Dec 31, 2024 | 605,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Dec 31, 2023 | 226,000.00 |
| Jun 30, 2023 | 278,000.00 |
| Dec 31, 2022 | 362,000.00 |
| Jun 30, 2022 | 2.52 Mn |
| Dec 31, 2021 | 1.74 Mn |
| Jun 30, 2021 | 4.01 Mn |
| Dec 31, 2020 | 4.01 Mn |
| Dec 31, 2019 | 2.51 Mn |